m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03592)
Name
ISIS 114170
Status
Investigative
TTD Drug ID
D0G8CN
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
E2F3 messenger RNA (E2F3 mRNA)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114170. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 114170 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA). [1], [2]
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114170. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 114170 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA). [1], [2]
References
Ref 1 Identification of pathology-specific regulators of m(6)A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. EPMA J. 2020 Jul 29;11(3):485-504. doi: 10.1007/s13167-020-00220-3. eCollection 2020 Sep.
Ref 2 US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.